The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20038760.
- Also identified by DOI 10.1212/WNL.0b013e3181c97e39.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
OBJECTIVE: Glatiramer acetate (formerly known as copolymer 1) is the major noninterferon immunomodulatory agent used in the treatment of relapsing-remitting multiple sclerosis. Its mechanism of action over the past 40 years has evolved with our understanding of the immune response. METHODS: We review the various mechanisms that have been proposed for this random polymer over the years, with emphasis on recent methods that utilize modern immunologic techniques. RESULTS: Studies describing processes such as immune deviation and effects on regulatory T cells and antigen-presenting cells are presented. CONCLUSIONS: Effects of glatiramer acetate on the immune response have evolved as our technical abilities and knowledge of the immune response itself have developed.